Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Andrology

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 23 articles:
HTML format



Single Articles


    July 2020
  1. CALLEC L, Lardy-Cleaud A, Guerrini-Rousseau L, Alapetite C, et al
    Relapsing intracranial germ cell tumours warrant retreatment.
    Eur J Cancer. 2020;136:186-194.
    PubMed     Abstract available


    May 2020
  2. CHOI MC, Chung YS, Lee JW, Kwon BS, et al
    Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
    Eur J Cancer. 2020;133:56-65.
    PubMed     Abstract available


    April 2020
  3. SEIDEL C, Daugaard G, Nestler T, Tryakin A, et al
    Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3).
    Eur J Cancer. 2020;132:127-135.
    PubMed     Abstract available


    March 2020
  4. BERNEY DM, Shamash J, Stoneham S, Lockley M, et al
    Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2020 Mar 18. pii: S0959-8049(20)30048.
    PubMed    


  5. PASHANKAR F, Frazier AL
    Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2020 Mar 13. pii: S0959-8049(20)30047.
    PubMed    


  6. GILBERT A, Drinkwater K, McParland L, Adams R, et al
    UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes.
    Eur J Cancer. 2020;128:7-16.
    PubMed     Abstract available


    January 2020
  7. CAFFERTY FH, White JD, Shamash J, Hennig I, et al
    Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II
    Eur J Cancer. 2020;127:139-149.
    PubMed     Abstract available


    July 2019
  8. DEPANI S, Stoneham S, Krailo M, Xia C, et al
    Results from the UK Children's Cancer and Leukaemia Group study of extracranial germ cell tumours in children and adolescents (GCIII).
    Eur J Cancer. 2019;118:49-57.
    PubMed     Abstract available


    April 2019
  9. NEWTON C, Murali K, Ahmad A, Hockings H, et al
    A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2019;113:19-27.
    PubMed     Abstract available


    May 2018
  10. FRAZIER AL, Stoneham S, Rodriguez-Galindo C, Dang H, et al
    Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium.
    Eur J Cancer. 2018;98:30-37.
    PubMed     Abstract available


    April 2018
  11. MOKE DJ, Thomas SM, Hiemenz MC, Nael A, et al
    Three synchronous malignancies in a patient with DICER1 syndrome.
    Eur J Cancer. 2018;93:140-143.
    PubMed    


    March 2018
  12. ALIFRANGIS C, Wilson P, Shamash J
    Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours-A comment on: 'Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment
    Eur J Cancer. 2018 Mar 31. pii: S0959-8049(18)30226.
    PubMed    


  13. FRESNEAU B, Orbach D, Faure-Conter C, Sudour-Bonnange H, et al
    Is alpha-fetoprotein decline a prognostic factor of childhood non-seminomatous germ cell tumours? Results of the French TGM95 study.
    Eur J Cancer. 2018;95:11-19.
    PubMed     Abstract available


  14. SEIDEL C, Daugaard G, Tryakin A, Necchi A, et al
    Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.
    Eur J Cancer. 2018;94:16-25.
    PubMed     Abstract available


  15. ABIUSO AMB, Varela ML, Haro Durand L, Besio Moreno M, et al
    Histamine H4 receptor as a novel therapeutic target for the treatment of Leydig-cell tumours in prepubertal boys.
    Eur J Cancer. 2018;91:125-135.
    PubMed     Abstract available


    January 2018
  16. DUHIL DE BENAZE G, Pacquement H, Faure-Conter C, Patte C, et al
    Paediatric dysgerminoma: Results of three consecutive French germ cell tumours clinical studies (TGM-85/90/95) with late effects study.
    Eur J Cancer. 2018;91:30-37.
    PubMed     Abstract available


    November 2017
  17. LORIOT Y, Pagliaro L, Flechon A, Mardiak J, et al
    Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
    Eur J Cancer. 2017;87:140-146.
    PubMed     Abstract available


    October 2017
  18. DE LA PENA H, Sharma A, Glicksman C, Joseph J, et al
    No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer.
    Eur J Cancer. 2017;84:354-359.
    PubMed     Abstract available


  19. VERMEULEN RFM, Beurden MV, Kieffer JM, Bleiker EMA, et al
    Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    Eur J Cancer. 2017;84:159-167.
    PubMed     Abstract available


    July 2017
  20. BANDAK M, Jorgensen N, Juul A, Lauritsen J, et al
    Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors.
    Eur J Cancer. 2017;84:9-17.
    PubMed     Abstract available


    May 2017
  21. ZSCHABITZ S, Lasitschka F, Hadaschik B, Hofheinz RD, et al
    Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Eur J Cancer. 2017;76:1-7.
    PubMed     Abstract available


    March 2017
  22. GIZZI M, Oberic L, Massard C, Poterie A, et al
    Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [Eur J Cancer 69 (2016) 151-157].
    Eur J Cancer. 2017 Mar 7. pii: S0959-8049(17)30740.
    PubMed    


    November 2016
  23. GIZZI M, Oberic L, Massard C, Poterie A, et al
    Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.
    Eur J Cancer. 2016;69:151-157.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Andrology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: